PL1706383T3 - Sól aminowa pochodnej karbostyrylowej użyteczna do leczenia między innymi wrzodu żołądka - Google Patents

Sól aminowa pochodnej karbostyrylowej użyteczna do leczenia między innymi wrzodu żołądka

Info

Publication number
PL1706383T3
PL1706383T3 PL05704144T PL05704144T PL1706383T3 PL 1706383 T3 PL1706383 T3 PL 1706383T3 PL 05704144 T PL05704144 T PL 05704144T PL 05704144 T PL05704144 T PL 05704144T PL 1706383 T3 PL1706383 T3 PL 1706383T3
Authority
PL
Poland
Prior art keywords
treatment
inter alia
amine salt
gastric ulcer
derivative useful
Prior art date
Application number
PL05704144T
Other languages
English (en)
Inventor
Yoshihiro Nishioka
Shinji Aki
Shigekazu Fujita
Yoshinao Onishi
Shun-Ichiro Sumida
Original Assignee
Otsuka Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Company Ltd filed Critical Otsuka Pharmaceutical Company Ltd
Publication of PL1706383T3 publication Critical patent/PL1706383T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05704144T 2004-01-21 2005-01-20 Sól aminowa pochodnej karbostyrylowej użyteczna do leczenia między innymi wrzodu żołądka PL1706383T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004013402 2004-01-21
EP05704144.4A EP1706383B1 (en) 2004-01-21 2005-01-20 Amine salt of carbostyril derivative useful for the treatment of, inter alia, gastric ulcer
PCT/JP2005/001034 WO2005070892A1 (en) 2004-01-21 2005-01-20 Amine salt of carbostyril derivative

Publications (1)

Publication Number Publication Date
PL1706383T3 true PL1706383T3 (pl) 2015-12-31

Family

ID=34805383

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10174397T PL2253619T3 (pl) 2004-01-21 2005-01-20 Sól aminowa pochodnej karbostyrylowej
PL05704144T PL1706383T3 (pl) 2004-01-21 2005-01-20 Sól aminowa pochodnej karbostyrylowej użyteczna do leczenia między innymi wrzodu żołądka

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10174397T PL2253619T3 (pl) 2004-01-21 2005-01-20 Sól aminowa pochodnej karbostyrylowej

Country Status (22)

Country Link
US (2) US7732611B2 (pl)
EP (2) EP2253619B1 (pl)
JP (1) JP4516962B2 (pl)
KR (1) KR100844762B1 (pl)
CN (1) CN1934086B (pl)
AR (1) AR047438A1 (pl)
AT (1) ATE549318T1 (pl)
AU (1) AU2005206430B2 (pl)
BR (1) BRPI0506982A (pl)
CA (1) CA2553231C (pl)
CY (2) CY1112723T1 (pl)
DK (2) DK1706383T3 (pl)
ES (2) ES2382133T3 (pl)
HU (1) HUE027990T2 (pl)
MY (1) MY148416A (pl)
PL (2) PL2253619T3 (pl)
PT (2) PT1706383E (pl)
RU (1) RU2372336C2 (pl)
SG (1) SG149854A1 (pl)
SI (2) SI1706383T1 (pl)
TW (1) TWI340650B (pl)
WO (1) WO2005070892A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187197B1 (en) * 1998-10-28 2001-02-13 Marvin Haddock Multi-stage engine coolant recycling process
TWI340650B (en) * 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
WO2009022674A1 (en) * 2007-08-10 2009-02-19 Otsuka Pharmaceutical Co., Ltd. Medical composition containing rebamipide
US9486418B2 (en) 2008-04-08 2016-11-08 Dynamis Pharmaceuticals, Inc. Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
TWI495634B (zh) * 2008-06-19 2015-08-11 Otsuka Pharma Co Ltd 醫藥組成物
WO2012114317A1 (en) * 2011-02-25 2012-08-30 Nuformix Limited Novel rebamipide complexes and cocrystals

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS517614Y2 (pl) * 1971-02-12 1976-03-01
JPS597168A (ja) 1982-07-05 1984-01-14 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US4578381A (en) 1982-07-05 1986-03-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1992021342A1 (en) * 1991-06-07 1992-12-10 Otsuka Pharmaceutical Co., Ltd. Antidiabetic
TW227558B (pl) * 1992-05-14 1994-08-01 Otsuka Pharma Co Ltd
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
JP2872546B2 (ja) * 1992-11-26 1999-03-17 大塚製薬株式会社 腸粘膜障害保護剤
WO1995011026A1 (en) * 1993-10-21 1995-04-27 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative for inhibiting production of interleukin-8
WO1995012579A1 (en) 1993-11-05 1995-05-11 Otsuka Pharmaceutical Company, Limited Bismuth salt of carbostyril derivatives for the treatment of peptic ulcers
JP3621463B2 (ja) 1995-04-26 2005-02-16 大塚製薬株式会社 カルボスチリル誘導体ビスマス塩
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
CN1274668C (zh) 2002-03-11 2006-09-13 诺瓦提斯公司 那格列奈的盐
KR20040104020A (ko) 2003-06-02 2004-12-10 진양제약주식회사 신규 레바미피드 리지네이트와 레바미피드 아르기니네이트및 이 신규 레바미피드 리지네이트와 레바미피드아르기니네이트를 유효성분으로 함유하는 약학적 제제
TWI340650B (en) * 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
JP4719917B2 (ja) 2007-03-30 2011-07-06 国立大学法人 岡山大学 アズキ加工食品のアズキ原料品種判定方法

Also Published As

Publication number Publication date
DK1706383T3 (en) 2015-08-03
HK1148527A1 (en) 2011-09-09
ES2544327T3 (es) 2015-08-28
AU2005206430B2 (en) 2008-12-11
US8222276B2 (en) 2012-07-17
SI1706383T1 (sl) 2015-09-30
BRPI0506982A (pt) 2007-07-03
KR100844762B1 (ko) 2008-07-07
JP2007514641A (ja) 2007-06-07
ATE549318T1 (de) 2012-03-15
SI2253619T1 (sl) 2012-04-30
TW200529873A (en) 2005-09-16
HK1101327A1 (en) 2007-10-12
EP1706383A1 (en) 2006-10-04
EP2253619A1 (en) 2010-11-24
US20070155787A1 (en) 2007-07-05
KR20060123566A (ko) 2006-12-01
CA2553231C (en) 2012-03-13
HUE027990T2 (en) 2016-11-28
PT1706383E (pt) 2015-10-15
CA2553231A1 (en) 2005-08-04
AR047438A1 (es) 2006-01-18
ES2382133T3 (es) 2012-06-05
RU2006129945A (ru) 2008-02-27
MY148416A (en) 2013-04-30
JP4516962B2 (ja) 2010-08-04
PT2253619E (pt) 2012-03-29
AU2005206430A1 (en) 2005-08-04
CN1934086B (zh) 2013-01-02
RU2372336C2 (ru) 2009-11-10
CY1116773T1 (el) 2017-03-15
SG149854A1 (en) 2009-02-27
US20100210684A1 (en) 2010-08-19
EP2253619B1 (en) 2012-03-14
CY1112723T1 (el) 2016-02-10
DK2253619T3 (da) 2012-04-16
CN1934086A (zh) 2007-03-21
PL2253619T3 (pl) 2012-08-31
TWI340650B (en) 2011-04-21
EP1706383B1 (en) 2015-07-22
WO2005070892A1 (en) 2005-08-04
US7732611B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
AP2327A (en) Quinoline derivatives for the treatment of latent tuberculosis.
IL190137A0 (en) Crystals of laquinimod sodium, and process for the manufacture thereof
IL208963A0 (en) Substituted quinoline compounds
IL187695A0 (en) N-(pyridin-2-yl)-sulfonamide derivatives
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
IL181897A0 (en) Cyclic amine derivative or salt thereof
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IL186748A0 (en) 4 - phenyl - 5 - oxo 1, 4, 5, 6, 7, 8 - hexahydroquinoline derivatives for the treatment of infertility
PL377464A1 (pl) Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
IL181332A0 (en) Prostaglandin derivatives for treating gastrointestinal disorder
PT1706383E (pt) Sal de amina de um derivado de carboestirilo útil para o tratamento de inter alia, úlcera gástrica
ZA200703495B (en) Process for the preparation of irbesartan hydrochloride
ZA200509590B (en) Nitrogen-containing heteroaryl derivatives for the treatment of HCV-infection
ZA200705160B (en) Quinoline derivatives for the treatment of latent tuberculosis
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
IL179670A0 (en) Heterocyclic compounds and processes for the preparation thereof
EP1919871A4 (en) PROCESS FOR SYNTHESIS OF CHINOLINE DERIVATIVES
IL174043A0 (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
ZA200605575B (en) Substituted quinoline compounds
ZA200702625B (en) Prostaglandin derivatives for treating gastrointestinal disorder
ZA200702193B (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
GB0428061D0 (en) Novel Quinoline Compounds